COAG

Hemab Therapeutics Holdings, Inc.

Latest Form 4:Purchase$153KbyRA CAPITAL MANAGEMENT, L.P. (10% Owner) · filed Jun 17, 2026

Hemab Therapeutics Holdings, Inc. (COAG) has 7 SEC Form 4 filings (22 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Jun 17, 2026.

The most active filer is 10% Owner RA CAPITAL MANAGEMENT, L.P. with 11 filings. Insiders have net bought $55.5M over the trailing 6 months. The largest single insider purchase in this window was $48.1M by Director, 10% Owner RA CAPITAL MANAGEMENT, L.P. on May 4, 2026.

  • Industry:Biotechnology
  • CEO:Benny Sorensen
  • Employees:59
  • HQ:Cambridge, MA, US
  • IPO:2026-05-01

Insider Buying

$55.5M

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Unique Insiders

1

in the rolling window

Market Cap

$2.1B

latest known value

Source
Purchase$153KJun 17SEC ↗
Purchase$1.5MJun 17SEC ↗
Purchase$95KMay 21SEC ↗
Purchase$25KMay 21SEC ↗
Purchase$159KMay 14SEC ↗
Purchase$242KMay 11SEC ↗
Purchase$37KMay 11SEC ↗
Purchase$989KMay 11SEC ↗
Purchase$48.1MMay 6SEC ↗
Purchase$2.4MMay 6SEC ↗
Purchase$1.7MMay 6SEC ↗

Related companies

Hemab Therapeutics Holdings, Inc. is in the Healthcare sector.